Impact of bevacizumab on survival outcomes in primary tumor resected metastatic colorectal cancer

Basit Öğe Kaydı
dc.authoridHacıbekiroğlu, İlhan/0000-0002-0333-7405
dc.authoridCicin, Irfan/0000-0002-7584-3868
dc.authoridGürkan, Hakan/0000-0002-8967-6124;
dc.authorwosidHacıbekiroğlu, İlhan/JCN-7264-2023
dc.authorwosidCicin, Irfan/AAQ-5575-2020
dc.authorwosidGürkan, Hakan/AAF-2866-2020
dc.authorwosidErdogan, Bulent/AAA-9781-2021
dc.contributor.authorKodaz, Hilmi
dc.contributor.authorErdogan, Bulent
dc.contributor.authorHacibekiroglu, Ilhan
dc.contributor.authorTurkmen, Esma
dc.contributor.authorGurkan, Hakan
dc.contributor.authorAlbayrak, Dogan
dc.contributor.authorTastekin, Ebru
dc.date.accessioned2024-06-12T10:54:26Z
dc.date.available2024-06-12T10:54:26Z
dc.date.issued2015
dc.departmentTrakya Üniversitesien_US
dc.description.abstractWe have studied the efficacy of bevacizumab in colorectal cancer with unresectable metastasis patients who had undergone resection of primary tumor. The patients with unresectable metastasis during diagnosis who had undergone resection of primary tumor without chemotherapy and the patients without resection of primary tumor were included. Among patients who had met the inclusion criteria, 46 patients with resection of primary tumor and 47 without resection of primary tumor were included in the study. A total of 93 unresectable metastatic colorectal cancer patients were included in the study. Median PFS was 9 months (95 % CI 7.37-10.62) in patients with resected primary tumor and bevacizumab containing first-line chemotherapy combination. Median PFS was 10 months (95 % CI 8.06-11.93) in patients without bevacizumab (P = 0.66) Median OS was 25 months (95 % CI 17.92-32.07) in patients with resected primary tumor and bevacizumab containing first-line chemotherapy combination. Median OS was 16 months (95 % CI 9.71-22.28) in patients without bevacizumab (P = 0.36) Median OS was 16 months (95 % CI 13.06-8.939) in patients without resected primary tumor and bevacizumab containing first-line chemotherapy combination. Median OS was 9 months (95 % CI 1.48-16.51) in patients without bevacizumab (P = 0.012). Bevacizumab seems ineffective in mCRC patients with resected primary tumor. An increase in number of retrospective literature data and randomized, prospective studies is required about this subject.en_US
dc.identifier.doi10.1007/s12032-014-0441-6
dc.identifier.issn1357-0560
dc.identifier.issn1559-131X
dc.identifier.issue1en_US
dc.identifier.pmid25502088en_US
dc.identifier.scopus2-s2.0-84920112616en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1007/s12032-014-0441-6
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19053
dc.identifier.volume32en_US
dc.identifier.wosWOS:000347775200095en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherHumana Press Incen_US
dc.relation.ispartofMedical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBevacizumaben_US
dc.subjectPrimary Tumor Resectionen_US
dc.subjectColorectal Canceren_US
dc.subjectEndothelial Growth-Factoren_US
dc.subject1st-Line Treatmenten_US
dc.subjectFluorouracilen_US
dc.subjectChemotherapyen_US
dc.subjectLeucovorinen_US
dc.subjectCetuximaben_US
dc.subjectBenefiten_US
dc.subjectVegfen_US
dc.titleImpact of bevacizumab on survival outcomes in primary tumor resected metastatic colorectal canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu